about
Prediction and preliminary validation of oncogene regulation by miRNAsMultiple Wnt/ß-catenin responsive enhancers align with the MYC promoter through long-range chromatin loopsIntrinsically disordered proteins are potential drug targetsContact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug deliveryUtilization of genomic signatures to identify phenotype-specific drugsDrug target prediction and repositioning using an integrated network-based approachc-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformationECA39 is a novel distant metastasis-related biomarker in colorectal cancerp27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.Postnatal liver growth and regeneration are independent of c-myc in a mouse model of conditional hepatic c-myc deletionA genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets.Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformationModelling Myc inhibition as a cancer therapy.A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.Small molecule growth inhibitors of human oncogenic gammaherpesvirus infected B-cellsSmall Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.Chemical intervention of the NM23-H2 transcriptional programme on c-MYC via a novel small molecule.The Interplay between Myc and CTP Synthase in Drosophila.microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion.Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc.Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein.Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model.Differences in protein expression and gene amplification of cyclins between colon and rectal adenocarcinomas.The myc 3' wnt-responsive element suppresses colonic tumorigenesis.Targeting RNA polymerase I to treat MYC-driven cancer.Elastin-like polypeptide for improved drug delivery for anticancer therapy: preclinical studies and future applications.Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.c-myc in whitefish (Coregonus lavaretus): structure, expression, and insights into possible posttranscriptional regulatory mechanism.MiR-449c targets c-Myc and inhibits NSCLC cell progression.Insights into genetic alterations of liver metastases from uveal melanoma.ZNF281 contributes to the DNA damage response by controlling the expression of XRCC2 and XRCC4.Amplification of chromosome 8 genes in lung cancer.The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.
P2860
Q21262991-2B5806A6-263B-4151-A997-2E937211CD22Q24300934-07C559F8-73DA-43E5-813F-843BCEF77CF3Q24633854-87A9616E-8753-408E-ADCA-25CBBD2792C7Q26795703-B549C0B8-6E92-4167-9E74-9E0ED098EDCEQ28476014-FBD902E2-441A-4C45-B019-D1F62DF1B814Q28485990-A6061A42-1025-467B-8A78-3D4CCBC33E3CQ28573044-79E90A44-FDDF-4B16-A678-381D01038CFAQ33909844-EFB806F7-374F-417E-AEF7-BFB4D734A9ADQ34186642-5D9A0959-DDDC-4C27-9A35-F38C166AA354Q34187598-A39EEAEE-7354-439E-AE58-4C59EE621A3BQ34433320-B197931E-EACD-4271-AB0D-103223AD0551Q34536441-15801DAC-7E7E-4B9D-AA86-29940F687CD2Q34811008-309CD03C-A517-4116-B0ED-07F442E75799Q34983995-C4F47E5A-EE98-4C0C-B2A5-114A9E9539FDQ35007967-A6D7A5AB-9E7B-48AF-885C-394F0F056781Q35590573-9E957D42-55EC-4980-8C9D-39312A44808DQ35676297-B20CA348-3404-44E8-B612-760F5C0243D5Q35926979-65FBF41C-4983-4CE8-BD7F-482555FA3539Q35937111-3C82B220-7EF0-4C69-8AF3-70D365793101Q36140644-10291C7C-8D6E-4D65-A108-65C317245481Q36638977-4175CCE1-A836-4092-A41A-528A8F21EB64Q37291966-1BF07EB9-8457-4820-8733-BBD9FC3B3B47Q37395726-ECFE6B6F-447E-4CC1-B319-6CA65D3C02A7Q37484830-3998EF35-95AD-44DC-A014-487D8F37BE55Q37713641-4926E431-4F20-4463-9166-38EE8E788D78Q38194418-CDB8EBE9-8ADB-42BA-9464-7E7242073347Q38263314-45880868-FD79-4274-BE2A-05758B79B681Q38648453-841B80BC-FC8C-4AEA-AEA1-0A78706F7820Q39004284-CEF158FD-E6AF-4745-80B7-8C49F3BCD1A3Q39178996-036B3532-9457-4334-BFDD-441C27C1744AQ40368091-765193B3-522A-4EC3-9822-FA597ED9384AQ40614989-F9914331-3B2B-4BA7-ABA0-5E6E1FE48AE6Q41837923-3A464D6C-3E14-446F-82BB-05EFF43122FEQ41868661-B3955CB8-B86A-4189-9FF3-A93021C800B4Q42115767-56FA0F9C-32A7-4302-9405-247BF61A1EE0
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
c-Myc as a therapeutic target in cancer.
@ast
c-Myc as a therapeutic target in cancer.
@en
type
label
c-Myc as a therapeutic target in cancer.
@ast
c-Myc as a therapeutic target in cancer.
@en
prefLabel
c-Myc as a therapeutic target in cancer.
@ast
c-Myc as a therapeutic target in cancer.
@en
P2860
P356
P1476
c-Myc as a therapeutic target in cancer.
@en
P2093
Edward V Prochownik
P2860
P304
P356
10.1586/14737140.4.2.289
P577
2004-04-01T00:00:00Z